Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

As returns falter in the U.S., VC firms are finding that infrastructure investments overseas are opening up uncharted territory for the life sciences industry.

You may also be interested in...



Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)

With private-equity investments in early-stage financing gone, corporate venture needs to support these opportunities, “because if you don’t, the biotechnology industry is going to disappear. It’s just going to dry up,” Martin maintains.

Takeda Research Investment’s Graeme Martin on Corporate Venture Capital’s New Role In Developing Next-Generation Biologics: An Interview With PharmAsia News (Part 1 of 2)

Attend any industry conference these days, and a general theme will appear that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage research, could impact long-term future development of emerging biotechnologies. Graeme Martin, president of Takeda's corporate venture arm Takeda Research Investment, talks with PharmAsia News about the changing scope of corporate venture capital in this atmosphere as well as the role of CVC in helping inform companies' development strategies.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS071363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel